Revenue (Q4 2024): $6.7 million, exceeding the midpoint of the previously announced outlook by approximately $600,000. Revenue (Fiscal Year 2024): $26.6 million, a decrease of $16.8 million compared to the prior year. GAAP Gross Margin (Q4 2024): Negative 14.9%. Non-GAAP Gross Margin (Q4 2024): Negative 5.2%. GAAP Gross Margin (Fiscal Year 2024): 1.3%. Non-GAAP Gross Margin (Fiscal Year 2024): 8%. GAAP Operating Expenses (Q4 2024): $5.6 million. Non-GAAP Operating Expenses (Q4 2024): $4.1 million. GAAP Net Loss (Q4 2024): $4.3 million or $0.19 per share. Non-GAAP Adjusted EBITDA (Q4 2024): Negative $4.5 million. GAAP Net Loss (Fiscal Year 2024): $25.9 million or $1.14 per share. Non-GAAP Adjusted EBITDA (Fiscal Year 2024): Negative $15.8 million. Cash and Cash Equivalents (End of Q4 2024): $135.9 million. Q1 2025 Revenue Guidance: $4.8 million to $5.1 million.

Warning! GuruFocus has detected 3 Warning Signs with INVE.

Release Date: March 05, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

Identiv Inc (NASDAQ:INVE) successfully transitioned 75% of its RFID production from Singapore to a low-cost facility in Thailand, which is expected to improve gross margins. The company has a strong financial position with $135.9 million in cash and cash equivalents, enabling it to pursue organic and inorganic growth initiatives. Identiv Inc (NASDAQ:INVE) has launched several new high-value customer-driven projects, including smart labels for home appliances and pharmaceutical cold chains. A strategic partnership with Novanta has been established to enhance medical device technology, potentially expanding market reach in the healthcare sector. The company has implemented a Perform, Accelerate, Transform (PAT) strategic framework to drive growth and optimize operations, with a focus on high-margin opportunities.

Negative Points

Fourth quarter 2024 GAAP and non-GAAP gross margins were negative, impacted by decreased utilization and transition costs associated with the move to Thailand. The company reported a GAAP net loss from continuing operations of $4.3 million for the fourth quarter of 2024, an increase from the previous year. Non-GAAP adjusted EBITDA for Q4 2024 was negative $4.5 million, reflecting lower year-over-year revenues and underutilization of production facilities. Fiscal year 2024 revenue decreased by $16.8 million compared to the prior year, primarily due to lower sales of BLE transponder and mobile products. Operating expenses increased year-over-year, with significant costs related to strategic transactions and stock-based compensation.

Story Continues

Q & A Highlights

Q: Can you expand on the partnership with Novanta and discuss any revenue or gross margin targets associated with it? A: The partnership with Novanta is primarily a technology and business development collaboration, focusing on integrating smart technology into medical devices. While there isn't direct revenue from Novanta, the partnership enhances our channel access in the healthcare market. For commercial partnerships, we do set revenue and gross margin targets, particularly aiming for higher margins in the healthcare sector due to its complexity. - Kirsten Newquist, CEO

Q: Regarding the grocery store BLE device opportunity, when do you expect it to impact revenue, and how does its ASP compare to your typical range? A: The BLE device is at a higher price point than our typical products. We aim to have early volumes by the end of this year or early next year. The device is being developed for a harsh environment, and once ready, it will be integrated into hundreds of millions of plastic pallets. - Kirsten Newquist, CEO

Q: Can you provide details on the Q4 pull-in order and its impact on revenue? A: The pull-in order was significant, contributing to a $600,000 revenue beat versus consensus. This was primarily due to a customer accelerating their delivery schedule from Q1 2025 to Q4 2024. - Justin Scarpulla, CFO

Q: How should we think about the cadence of gross margin throughout the year, especially with the transition of the remaining customers to Thailand? A: While we don't provide detailed guidance beyond one quarter, we are on track with the transition to Thailand, which should positively impact gross margins. The consensus on margin is directionally accurate. - Justin Scarpulla, CFO

Q: Do you expect 2025 to be a growth year given the current pipeline and new engagements? A: While we can't provide specific guidance, we are excited about the projects in development. These projects will likely contribute more significantly to growth in 2026. - Kirsten Newquist, CEO

Q: Is there a timeline for achieving EBITDA breakeven, and are there any tariff risks with the transition to Thailand? A: We haven't set a formal timeline for EBITDA breakeven. Regarding tariffs, being in Thailand positions us well, and we've confirmed with vendors that we are in a good spot concerning tariffs. - Justin Scarpulla, CFO

Q: For the three customers transitioning from Singapore to Thailand, will this impact revenue, and are they lower margin customers? A: The transition is smooth, with no disruption to revenue. These customers are not lower margin; the transition is more about manufacturing location rather than revenue impact. - Justin Scarpulla, CFO

Q: Will operating expenses remain flat, or do you expect changes in 2025? A: Operating expenses will see a slight increase due to merit increases and strategic hires in R&D and business development. However, the increase will not be significant. - Justin Scarpulla, CFO

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

This article first appeared on GuruFocus.

View Comments